Management of Renal Cell Carcinoma and Other Renal Masses in the Kidney Graft
AbstractPurpose of ReviewRenal masses in the kidney graft pose an important clinical dilemma, balancing graft function against the need for cancer control.Recent FindingsDonor origin cancers in the renal graft can be classified as ‘donor transmitted’ or ‘donor derived’. The landmark TracerX Renal changed our understanding of renal cell carcinoma oncogenesis, demonstrating that key mutations in childhood lead to clinically apparent tumours in later life. Identified pre-operatively, contemporary evidence suggests that m asses excised prior to transplantation result in acceptable oncologic safety and graft function. Identified post-operatively management mirrors that for a mass in a solitary kidney in the non-transplant population, with focus on a nephron-sparing approach.SummaryWith growing number of kidney transplants each year, ageing donors, and increasing graft survival, masses in the renal graft are likely to become a more prevalent clinical conundrum.
Most women who are notified by mail that they have a high risk of breast cancer are unlikely to do anything about it, a small study suggests.Reuters Health Information
Publication date: Available online 5 March 2020Source: Joint Bone SpineAuthor(s): Alix Frain de La Gaulayrie, Benoît Gobron, Béatrice Bouvard
ConclusionsOur study reveals the need for targeted patient ‐education about the benefits and limitations of follow‐up. In order to meet increasing costs of cancer care, individualized follow‐up procedures adjusted to risk of recurrence and late‐effects in cervical cancer survivors are warranted.
Publication date: June 2020Source: Journal of Functional Foods, Volume 69Author(s): Gengzhen Huang, Shiqing Li, Yaodan Zhang, Xiaoqing Zhou, Wei Chen
Radiation therapy vendor Varian Medical Systems has added new artificial intelligence...Read more on AuntMinnie.comRelated Reading: Varian gets FDA nod for Ethos adaptive therapy unit Varian posts strong Q1 sales growth as profit slips Varian installs systems in Africa, U.S. Varian awarded Mich. cancer software contract Varian posts continued revenue gains in Q4, fiscal 2019
AbstractNeuropathic pain (NeP) is an intractable pain caused by a lesion or disease of the somatosensory nervous system. NeP is often challenging to manage because most of the mechanisms remain to be elucidated. Recent investigations in the field of autoimmune neurology have demonstrated that specific autoantibodies against antigens in the somatosensory pathway can cause NeP. Detection of pathogenic autoantibodies in NeP adds to the understanding of the mechanism of pain, which might aid in the development of novel immunotherapies. Therefore, it is necessary to explore novel NeP ‐related autoantibodies to improve the man...
We’re tackling a few urgent questions from parents in this time of coronavirus and COVID-19. Are you wondering if babies and children should continue to have vaccines on schedule? Thinking about how to manage regular medical appointments, and which situations require in-person visits to a pediatric practice? Read on. Should parents take babies for initial vaccines right now? What about toddlers and older children who are due for vaccines? The answer to this question is going to depend on many factors, including what your doctor’s office is offering. As with all health care decisions, it comes down to weighing r...
Publication date: Available online 30 March 2020Source: Journal of EthnopharmacologyAuthor(s): Zu-Jun Que, Bin Luo, Chen-Tong Wang, Fang-Fang Qian, Yi Jiang, Yan Li, Xiang-Hui Han, He-Gen Li, Jia-Xiang Liu, Jian-Hui Tian
Publication date: Available online 30 March 2020Source: International Journal of PharmaceuticsAuthor(s): Afshin Nikkhoo, Narges Rostami, Shohreh Farhadi, Maryam Esmaily, Sadaf Moghadaszadeh Ardebili, Fatemeh Atyabi, Masoumeh Baghaei, Navideh Haghnavaz, Mehdi Yousefi, Mohammad Reza Aliparasti, Ghasem Ghalamfarsa, Hamed Mohammadi, Mozhdeh Sojoodi, Farhad Jadidi-Niaragh
This study evaluated the distribution of the crizotinib patient information brochure (PIB) in Europe and patient knowledge of the key messages in the PIB. A cross‐sectional survey was conducted in 10 European countries among pa tients who received crizotinib to ascertain whether each patient received and read the PIB, and his/her knowledge of its key messages on hepatotoxicity, interstitial lung disease/pneumonitis, QTc prolongation, bradycardia, and vision disorders. Of the 341 patients contacted, 40 responded (11.7%), an d 39 patients were eligible. A total of 77% of respondents acknowledged receiving the PIB, of which...